Cantor Fitzgerald Predicts HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Harmony Biosciences in a research note issued on Tuesday, May 13th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of $2.68 per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The company’s revenue was up 19.5% compared to the same quarter last year.

HRMY has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price for the company. Mizuho boosted their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. UBS Group cut their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, April 28th. Finally, Needham & Company LLC restated a “buy” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, May 6th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $52.78.

Harmony Biosciences Trading Up 2.5%

NASDAQ:HRMY opened at $34.23 on Thursday. Harmony Biosciences has a 1 year low of $26.47 and a 1 year high of $41.61. The stock has a market cap of $1.97 billion, a P/E ratio of 16.22, a P/E/G ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock has a 50-day simple moving average of $31.42 and a 200-day simple moving average of $34.00.

Institutional Trading of Harmony Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of HRMY. Financial Management Professionals Inc. acquired a new position in Harmony Biosciences in the first quarter valued at $29,000. GAMMA Investing LLC grew its holdings in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after buying an additional 436 shares during the last quarter. Mendota Financial Group LLC increased its position in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after acquiring an additional 965 shares during the period. Brooklyn Investment Group increased its position in Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock valued at $35,000 after acquiring an additional 970 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in Harmony Biosciences during the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.